Fig. 3: Survival outcomes with RWCP therapies. | Leukemia

Fig. 3: Survival outcomes with RWCP therapies.

From: LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

Fig. 3

Kaplan–Meier plots showing (A) progression-free survival and B overall survival based on RRC assessment at median study follow-up 26.4 months in all patients. OS overall survival, PFS progression-free survival, RRC response review committee, VGPR very good partial response.

Back to article page